Advanced pancreatic cancer
Conditions
Interventions
Case series:No
Sponsors
Department of Oncology, Shenzhen Second People's Hospital (The First Affiliated Hospital of Shenzhen University)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, including 18 years old and 75 years old; 2. ECOG PS score 0-2; 3. Patients with stage III-IV pancreatic cancer diagnosed by histopathology or cytology. If the patient refuses to puncture or the pancreatic pathological puncture is difficult, PET-CT, nuclear magnetic resonance, tumor markers (CA199, CA125, CEA) and other relevant evidence are required to support. (According to the 2020 CSCO Guidelines for the Diagnosis and Treatment of Pancreatic Tumors). 4. Histopathological immunohistochemistry or blood gene test showed positive EGFR expression 5. Second-line and above pancreatic cancer patients with recurrence and metastasis after standardized treatment; 6. According to the RECIST version 1.1 evaluation criteria, there is at least one measurable lesion; 7. Suitable for receiving chemotherapy treatment for the purpose of radical cure. 8. Expected survival time >= 3 months; 9. Hematological indicators are basically normal: white blood cell count >=4x10^9/L; absolute neutrophil count >=1.5x10^9/L; platelets >=100x10^9/L; hemoglobin >=90 g/L; 10. Basically normal renal function: serum creatinine=60mL/min 11. Liver function is basically normal: serum total bilirubin <=1.5xULN (if liver metastases, serum total bilirubin should be <=3.0xULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5xULN (<= 5.0xULN if there is liver metastases). 12. Sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Participated in other interventional clinical trials within 30 days before screening; 2. History of other malignant tumors (except for cured cervical carcinoma in situ or skin basal cell carcinoma and other malignant tumors that have been cured for more than 5 years); 3. There are concurrent diseases that are poorly controlled (such as heart failure, diabetes, hypertension, thyroid disease, mental illness, etc.); 4. Known HIV infection or active viral hepatitis; 5. Are receiving chronic steroid therapy for more than 6 months (such as prednisone dose > 10 mg/day or equivalent dose); 6. Those who are allergic to the drugs or their components used in this program; 7. According to the criteria of Common Adverse Event Terms (NCI CTCAE V5.0), >= grade 2 peripheral nerve disease or hearing loss; 8. Pregnant (confirmed by blood or urine HCG test) or lactating women, or subjects of childbearing age are unwilling or unable to take effective contraceptive measures (both male and female subjects) until at least after the last trial treatment 6 months; 9. The researcher believes that it is not suitable to participate in the researcher; 10. Those who are unwilling to participate in this study or unable to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to asymptomatic progression;overall survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Benefit rate of epidermal growth factor receptor-positive patients; | — |
Countries
China
Contacts
Public ContactXiao Liang
Department of Oncology, Shenzhen Second People's Hospital (The First Affiliated Hospital of Shenzhen University)
Outcome results
None listed